Abstract: A delayed release pharmaceutical formulation containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol or a pharmaceutically acceptable salt thereof in a matrix; said matrix containing from 1 to 80 wt. % of at least one pharmaceutically acceptable, matrix-forming, hydrophilic or hydrophobic polymer and having the following in vitro dissolution rate relative to 100 wt. % of the 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol contained in the formulation: 3-35 wt. % released after 0.5 hour, 5-50 wt. % released after 1 hour, 10-75 wt. % released after 2 hours, 15-82 wt. % released after 3 hours, 30-97 wt. % released after 6 hours, more than 50 wt. % released after 12 hours, more than 70 wt. % released after 18 hours, and more than 80 wt. % released after 24 hours.

Abstract: The invention relates to parenteral dosage forms of administration that comprise a suspension of the salt of the active substances tramadol and diclofenac.

Abstract: A pharmaceutical formulation for delayed release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.

Abstract: A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or a tramadol salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of treatment using the pharmaceutical formulations. Method for preparing such formulations are also provided. The preparation method comprises repeatedly mixing tramadol or its salt with the acidic substance, and moistening the mixture and formulating the mixture under an energy input, such as heat or pressure. Optionally, drying, repeated granulating, extrudation and pelleting may also be included.

Abstract: The invention deals with the use of buprenorphine for the production of a pharmaceutical composition in form of a transdermal system for the treatment of increased urinary urge, increased micturition frequency and/or urinary incontinence, especially urge incontinence, overactive bladder or stress-induced incontinence.

Abstract: Methods for the use of buprenorphine compounds for treating increased urinary urgency, increased micturition, and/or urinary incontinence are disclosed, as well as corresponding medicaments and the production thereof.

Abstract: An orally administered preparation with controlled lease of an opioid analgesic in the form of crystals having particle size of 10 &mgr;m to 3 mm, preferably of 50 &mgr;m to 1 mm, which have at least one controlled release coating.

Abstract: Disclosed herein is sustained-release formulations of tramadol comprising tramadol saccharinate coated with at least one sustained-release coating. The sustained release formulations may also contain tramadol in non-sustained release form, and other pharmaceutically acceptable excipients. Also disclosed are methods of preparation of and methods of treatment using the inventive formulations.

Abstract: A multilayer tablet for oral administration containing at least one Tramadol layer including Tramadol or a physiologically acceptable salt thereof; at least one diclofenac layer including diclofenac or a physiologically acceptable salt thereof, and at least one separating layer which separates the tramadol layer(s) and the diclofenac layer(s) from each other.

Abstract: A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or its salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of treatment using the pharmaceutical formulations. Method for preparing such formulations are also provided. The preparation method comprises repeatedly mixing tramadol or its salt with the acidic substance, and moistening the mixture and formulating the mixture under an energy input, such as heat or pressure. Optionally, drying, repeated granulating, extrudation and pelleting may also be included.

Abstract: Disclosed herein is sustained-release formulations of tramadol comprising tramadol saccharinate coated with at least one sustained-release coating. The sustained release formulations may also contain tramadol in non-sustained release form, and other pharmaceutically acceptable excipients. Also disclosed are methods of preparation of and methods of treatment using the inventive formulations.

Abstract: A controlled-release oral dosage formulation of a salt-forming active ingredient, wherein the active ingredient is present as at least two different salts in a solid aggregation state, wherein the two different salts have different water solubility and release the active ingredient in-vitro at different release rates, provided that oral dosage formulations are excluded which comprise a resin carrying a sulfonate group and a resin carrying a carboxyl group and which contain an active ingredient in a form fixed to these resins.

Abstract: An oral administration unit containing the active substances Tramadol and Diclofenac and/or physiologically acceptable salts thereof, in which both active substances are contained in the same administration unit as two separately formulated subunits.

Abstract: A multilayer tablet for oral administration containing at least one Tramadol layer including Tramadol or a physiologically acceptable salt thereof; at least one diclofenac layer including diclofenac or a physiologically acceptable salt thereof, and at least one separating layer which separates the tramadol layer(s) and the diclofenac layer(s) from each other.

Abstract: Pharmaceutical formulations containing an opioid, an &agr;-agonist and/or their physically compatible salts, from which at least one medicinally active ingredient is released in a sustained manner.

Abstract: Solid medicinal forms having a multiphase structure for oral administration, containing gatifloxacin or pharmaceutically acceptable salts or hydrates thereof and auxiliary substances selected from the group of fillers, binders, lubricants, disintegration aids and mixtures thereof, in which the inner phase contains the active ingredient gatifloxacin or pharmaceutically acceptable salts or hydrates thereof and auxiliary substances from the group of binders, fillers, disintegration aids and mixtures thereof, and at least one outer phase necessarily contains at least one disintegration aid and further auxiliary substances from the group of at least one lubricant, optionally fillers and/or optionally binders, and a process for the preparation of such solid medicinal forms.